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Dual antiplatelet treatment with aspirin and clopidogrel is the antithrombotic treatment recommended after an
acute coronary syndrome and/or coronary artery stenting. The evidence for optimal antiplatelet therapy for
patients, in whom long-term treatment oral anticoagulation is mandatory, is however scarce. To evaluate the safety
and efficacy of the various antithrombotic strategies adopted in this population, we reviewed the available
evidence on the management of patients receiving oral anticoagulation, such as a vitamin-k-antagonists, referred
for coronary artery stenting.
Atrial fibrillation is the most frequent indication for oral anticoagulation. The need of starting antiplatelet therapy in
this clinical scenario raises concerns about the combination to choose: triple therapy with warfarin, aspirin, and a
thienopyridine being the most frequent and advised. The safety of this regimen appeared suboptimal because of
an increased risk in hemorrhagic complications. On the other hand, the combination of oral anticoagulation and an
antiplatelet agent is suboptimal in preventing thromboembolic events and stent thrombosis; dual antiplatelet
therapy may be considered only when a high hemorrhagic risk and low thromboembolic risk are perceived. Indeed,
the need for prolonged multiple-drug antithrombotic therapy increases the bleeding risks when drug eluting stents
are used.
Since current evidence derives mainly from small, single-center and retrospective studies, large-scale prospective
multicenter studies are urgently needed.
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Long-term oral anticoagulation (OAC) with vitamin K
antagonists is recommended in patients with atrial fibril-
lation (AF) at moderate to high risk of stroke, those with
prosthetic heart valves, previous cardiogenic thrombo-
embolism, recent deep vein thrombosis or pulmonary
embolism [1-3].
In the event that also an indication for dual antiplate-
let therapy (DAPT) arises, mainly because of percutan-
eous coronary intervention with stent implantation
(PCI-S) [4], the management of these patients becomes* Correspondence: mila.menozzi@asmn.re.it
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reproduction in any medium, provided the orchallenging. It is estimated that about 5% of patients
undergoing percutaneous coronary interventions (PCI)
has atrial fibrillation or other indications for chronic oral
anticoagulant therapy [5]. Since DAPT provides insuffi-
cient protection against stroke and thrombotic compli-
cations in patients with AF and mechanical aortic valves
[6,7], substitution of OAC with DAPT appears not ap-
plicable. The issue therefore, is whether or not aspirin
and/or clopidogrel should be added to OAC in patients
who are referred for PCI-S.
To date, there are no large-scale studies or randomised
clinical trials involving this kind of patients, and their
management is often left to physician’s discretion. Triple
therapy (TT) with OAC, aspirin and clopidogrel is
reported to be the antithrombotic treatment mostl Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
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in patients with an indication for OAC [8].
In this paper we review the evidence supporting the
preferential use of TT in AF patients who are submitted
to PCI-S. Since the data available for patients with other
indications for OAC, such as prosthetic heart valves or
pulmonary embolism are extremely limited, these indica-
tions will not be covered.
Available evidence
Various combinations of key words such as oral anticoa-
gulation, warfarin, antiplatelet agents, percutaneous cor-
onary intervention, stent, were used for Medline search.
All English language full-text articles, from January
2004 to December 2011, reporting safety outcomes dur-
ing follow up in patients with indication for OAC trea-
ted with PCI-S were selected for this review. At present,
28 full reports on the safety and efficacy at follow up of
antithrombotic treatment in patients on OAC undergo-
ing PCI-S have been published [9-36]. These papers,
some of which have been recently meta-analyzed [37],
are summarized in Table 1. Although only seven of them
focused on AF patients [13,19,20,22,25,29,36], AF was
the prominent indication for OAC in most of the stud-
ies, so that considerations for clinical practice arising
from these studies can be extrapolated to the specific
subset of patients with AF.
None of the studies was randomized. Eleven studies spe-
cifically assessed the safety of TT of warfarin, aspirin and
a thienopyridine, and either no comparisons, or compari-
sons with contemporary populations with no indications
for OAC, receiving DAPT [9-12,15,18,23,30-32,35]. In the
remaining studies, the outcomes with different treatments
strategies adopted were compared within the population
examined [13,14,16,17,19-22,24-29,33,34,36]. Finally, a
wide variation in the length of follow-up and in the defini-
tions of the outcome measures was observed making their
comparison difficult.
Orford et al. [9] evaluated the safety of 30-day TT in
66 patients after PCI. Bleeding complications occurred
in 6 patients (9.2%). In 2 patients (3.1%), the hemor-
rhagic event was a melena and was classified as major,
since blood transfusions were required. In both patients,
the INR value at the time of bleeding was above the
therapeutic level (12.4 and 3.7, respectively). Minor
hemorrhages consisted of a groin hematoma, minor and
self-limiting nose and ear bleedings, and a gross he-
maturia, which were all treated conservatively with tem-
porary withdrawal of one or more antithrombotic agents.
No major cardiac events were observed.
Mattichak et al. [10] examined 40 patients with ST-
elevation acute myocardial infarction treated with pri-
mary PCI-S, and discharged on TT , and compared the
outcome to 42 contemporary primary PCI-S patientswith no indications for OAC. At 12 months, the occur-
rence of gastrointestinal bleedings with TT was high, al-
though not significantly different from the control group
with DAPT (15% vs. 9%; p=0.12). Also the need for
blood transfusions was higher with TT at 12 months
(21% vs. 3.5%, p=0.028).
Khurram et al. [11] evaluated 107 patients who were
treated up to 12 months with TT following PCI-S (drug-
eluting stents in 50% of cases). A contemporary cohort
of an additional 107 patients with no indication for OAC
who were discharged on DAPT after implantation of
drug eluting stents (DESs), served for comparison. The
incidence of both major and minor hemorrhages was
significantly higher in the TT group than in the control
population (6.6% vs. 0%, p=0.014, and 14.9% vs. 3.8%,
p=0.01, respectively). At multivariable analysis, TT was
found associated to an about 5-fold increase in hemor-
rhages as compared to DAPT (hazard ratio 5.44; 95%
confidence intervals 2.03-14.53 p=0.001). All major
bleedings occurred between 2 and 10 months, suggesting
that the duration of the three-drug regimen should be
minimized, e.g. by avoiding the use of DESs. One of the
major hemorrhagic complications was fatal intracranial
hemorrhage in a patient with a history of intracranial
bleeding. Neither stent thrombosis nor thromboembolic
events were observed during the triple antithrombotic
therapy.
In the study by Porter et al. [12], 180 patients under-
going PCI-S and discharged on TT were evaluated. AF
was the indication for VKA only in 37% of the patients.
At 30 days, bleeding complications occurred in 20
patients (11%), being classified as major (i.e., major groin
haematoma) in 2 of them (1%). Both major hemorrhagic
events occurred during the initial phase of warfarin and
heparin overlap. This period appears to be fragile since
18 out of the 20 bleedings observed took place during
the bridging period. Neither stent thrombosis nor
thromboembolism were observed in this study.
Lip and Karpha [13] included in their small study only
patients with AF. At discharge, the prescribed antith-
rombotic treatment in the 35 patients included was
highly variable: DAPT was given in 71% of cases, TT in
17%, clopidogrel alone in 6%, and the combination of
warfarin and one antiplatelet agent only (either aspirin
or clopidogrel) in the remaining 6%. At 30 days, no
bleeding complications requiring hospitalization were
observed.
Karjalainen et al. [14] evaluated a population of
patients with an indication for OAC undergoing PCI-S
at six Finnish hospitals. These 239 patients were then
compared with an age- and sex-matched control group
with no indication for OAC and discharged on DAPT
after PCI-S. The antithrombotic regimens prescribed in
these patients were found highly variable: TT in 48% of







Patients, n Prevalence of
AF in TT, %
DES, % TT at discharge,
%
Outcome comparisons, n Follow up,
months
Orford JL et al. [9] R/SC 2000-2002 2004 66 39 0 100 None 1
Mattichak SJ et al. [10] R/SC 2001 2005 40 43 0 100 Against contemporary patients on DAPT, 42 12
Khurram Z et al. [11] R/SC NR 2006 107 70 75 100 Against contemporary patients on DAPT, 107 7
Porter A et al. [12] R/SC 2000-2004 2006 180 37 0 100 None 15
Lip GYH & Karpha M [13] R/SC 2000-2005 2006 35 100 14 17 Within population 1
Karjalainen PP et al. [14] R/MC 2003-2004 2007 239 70 42 48 Within population and against
contemporary patients on DAPT, 239
12
DeEugenio D et al. [15] R/SC 2000-2005 2007 97 60 30 100 Against contemporary patients on DAPT, 97 6
Rubboli A et al. [16] R/SC 2002-2004 2007 49 60 0 41 Within population 1
Nguyen MC et al. [17] P/MC^ 1999-2006 2007 580 40 16 79 Within population 6
Rogacka RCA et al. [18] R/SC 1999-2006 2008 127 59 56 100 None 21
Ruiz-Nodar JM et al. [19] R/SC 2001-2006 2008 213 100 40 50 Within population 20
M.-Fernandez S et al. [20] R/SC 2002-2006 2008 104 100 66 49 Within population 12
Sarafoff N et al. [21] P/SC 2002-2007 2008 515 78 100 59 Within population 24
Maegdefessel L et al. [22] R/SC 1999-2004 2008 159 100 NR 9 Within population 16
Rossini R et al. [23] P/MC 2005-2006 2008 102 67 47 100 Against contemporary patients on DAPT, 102 18
Valencia J et al. [24] P/SC 2004-2006 2008 70 68 60 64 Within population 12
Gao F et al. [25] P/SC 2005-2008 2010 622 100 100 23 Within population 12
Sambola A et al. [26] P/MC 2003-2006 2009 405 67 46 68 Within population 6
Gilard M et al. [27] P/MC 2005-2006 2009 359 48 30 35 Within population 12
Hälg C et al. [28] R/MC 2003-2004 2009 813 NR 65.9 5 Within population 36
Halbfass P et al. [29] R/MC 2002-2006 2009 117 100 47 45 Within population 28
Helft G et al. [30] P/MC 2006-2007 2009 50 62 14 100 None 1
Olson KL et al. [31] R/SC 2003-2006 2009 175 23 81 100 Against contemporary patients on DAPT, 339 12
Baber J et al. [32] R/SC 2003-2007 2009 454 53 100 100* None*
Persson J et al. [33] P/MC^ 1997-2005 2010 1183 35 32 56 Within population 12
Uchidab Y et al. [34] R/SC 2004-2007 2010 575 5 100 9 Within population 15
Guasch E et al. [35] R/MC 2005-2006 2011 33 29 NR 100 Against same patients after stopping clopidogrel 922 pt/months
Jang SW et al. [36] R/MC 2005-2007 2011 362 100 91 20 Within population 615
OAC= oral anticoagulation; PCI-S= percutaneous coronary intervention with stent implantation; AF= atrial fibrillation;
DES= drug eluting stent; TT= triple therapy; R= retrospective study; P= prospective study; SC= single center; MC= multi center; DAPT= dual anti-platelet treatment; NR= not reported. ^ post-hoc * evaluation of
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dogrel in 15.5%, warfarin and aspirin in 15%, and war-
farin alone in 0.5%. At 12 months, stent thrombosis was
significantly more frequent in the warfarin plus aspirin
group (15.2%), whereas the lowest incidence was
observed with TT (1,9%) (p= 0.004). Occurrence of
stroke was also different between subgroups, being more
frequent in patients receiving DAPT (8.8% vs. 2.8% with
TT) (p= n.s.). Conversely, no significant differences were
observed between treatment subgroups in major bleed-
ings. Overall, the OAC group showed a 12-month mor-
tality (8.7% vs. 1.8%; p=0.003) and myocardial infarction
(10% vs. 4.8%; p= 0.041) rates significantly higher than
the DAPT group, although higher risk baseline features
need to be acknowledged.
DeEugenio et al. [15] examined the safety and efficacy
of TT in 97 patients undergoing PCI-S or brachytherapy.
A matched control group of 97 patients on DAPT and
no indication for OAC served for comparison. At 6
months, major bleedings were significantly more fre-
quent in the TT group: 14% vs. 3% (hazard ratio 5.0;
95% confidence intervals 1.40-17.80; p=0.012), and
mostly were gastrointestinal in location. Results of
multivariate analysis revealed that the risk of major
bleeding after PCI was 5 times higher for patients receiv-
ing TT compared with DAPT. The number needed to
harm was 9 additional patients treated with TT to cause
one major bleeding.
Rubboli et al. [16] evaluated 49 consecutive patients
with an indication for OAC undergoing PCI-S. The
antithrombotic regimens prescribed at discharge in these
patients was widely variable: aspirin and either ticlopi-
dine or clopidogrel in 45% of cases, TT with OAC (or
low-molecular-weight heparin), aspirin and a thienopyri-
dine in 41%, and the combination of warfarin and as-
pirin in 14%. At follow up of about 30 days, TT was
associated to a higher (albeit not statistically significant)
occurrence of bleeding complications: 20% vs. 4.5% (HR
5.25) compared to DAPT. Out of the 4 haemorrhages
observed in patients on the three-drug regimen, 3 were
major, as opposed to none in the aspirin plus thienopyri-
dine group. Of note, all major bleeding complications
occurring in the TT group were observed in the setting
of emergency PCI-S for ST-elevation myocardial infarc-
tion, and in patients either older than 75 years or having
received glycoprotein IIb/IIIa inhibitors or having under-
gone some traumatic manoeuvre. In one patient out of
the 7 receiving the combination of warfarin and aspirin
(14%) a subacute stent thrombosis requiring emergency
reintervention was observed.
Nguyen et al. [17] evaluated 580 patients who under-
went PCI-S for acute coronary syndromes and were dis-
charged on warfarin plus single (220) or dual (580)
antiplatelet agents as part of the GRACE (GlobalRegistry of Acute Coronary Events) registry. A signifi-
cant reduction in stroke was observed in patients receiv-
ing TT at 6 months (0.7% vs. 3.4%, p= 0.02). No
differences in major bleeding events were observed in-
hospital between patients receiving TT (5.9%) or those
treated with warfarin and a single antiplatelet agent
(4.6%) (p =0.46). No follow-up data on bleeding events
were presented.
A series of 127 patients [18] receiving warfarin who
were treated with PCI-S and discharged on TT demon-
strated a 7.1% total bleeding incidence (4.7% major) dur-
ing 21-month follow-up. Of note, major bleeding events
were fatal in 3 (50%) cases and were intracranial in 4
(approximately 66%) patients. These frequencies should,
of course, be interpreted cautiously in light of the small
number of events.
In the study by Ruiz-Nodar et al. [19] including 426
patients with AF who underwent PCI-S, TT was admi-
nistered to 213 (50%) patients. Adverse events were fre-
quent (35%) in the whole population: major bleeding
being reported in 12.3%, and all-cause mortality in 22.6%
of patients. Among the patients who were prescribed
OAC at discharge, there was a non-significant increase
in major bleeding (14.9% vs. 9.0%) but a significantly
better MACE-free prognosis as well as lower all-cause
mortality. Interruption of OAC after intervention was
associated with an increased risk of cardiovascular
events at a mean of 595 days (HR: 4.9, 95% CI: 2.17 to
11.09; p <0.01) and was largely driven by thrombo-
embolic complications. The clinical benefit of continuing
warfarin outweighed a 66% relative increase in risk of
major bleeding.
In 104 patients with AF undergoing PCI-S studied by
the same group [20], TT was the most commonly used
regimen (49%). In this report the authors differentiated
between early (≤48 hours) and late (>48 hours) major
bleedings. A high rate of late major bleeding was
observed in patients receiving TT (21.6% vs. 3.8% in
non-TT, p=0.006). At multivariable analysis use glyco-
protein II/IIIa inhibitor use and multivessel/left main
PCI-S were independent predictors of early major bleed-
ings; while TT use, occurrence of early major bleeding,
and baseline anemia were independent predictors of late
major bleedings.
The study by Sarafoff et al. [21] was the first that pro-
spectively analysed the safety and efficacy of TT com-
pared to DAPT in a population of patients on chronic
OAC all treated with DES. They used clinical and echo-
cardiographic criteria to select patients who continued
OAC (306 patients discharged with TT), in the other
group patients discontinued OAC for the time they
received DAPT (209 patients). The primary endpoint, a
composite of death, myocardial infarction, stent throm-
bosis or stroke, was less frequent in TT group (4.2% vs.
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up (14.1% vs. 18%), even though not statistically signifi-
cant. At two years, the incidence of major bleeding was
more frequent in DAPT group (3.1% vs. 1.4%, p= n.s.).
The authors concluded that both TT and DAPT were
associated with favourable safety and efficacy when the
post-procedural treatment was defined by clinical and
echocardiographic criteria.
In a German study including 159 patients with AF
undergoing PCI [22], Maegdefessel at al. compared
patients treated with either DAPT, a combination of
DAPT and low-molecular weight heparin, and TT. In a
median follow up of 1,4 years patients in DAPT experi-
enced the highest incidence of bleeding events (2 cases
vs. 0), myocardial infarction (4 cases vs. 0), stroke (9
cases vs. 4 in group 2 and 0 in group 3), and cardiovas-
cular death (3 cases vs. 5 in group 2, and 1 in group 3).
A prospective multicenter study performed at three
Italian institutions [23] enrolled 102 consecutive patients
requiring OAC undergoing PCI-S, compared with a con-
trol group of 102 patients treated with DAPT. At 18
months, a non significant increase in bleeding was
observed in the TT compared to the DAPT group (10.8%
vs. 4.9%, p= 0,1). International Normalized Ratio (INR)
values were significantly higher in patients with bleeding
(2.8 ± 1.1 vs. 2.3 ± 0.2, p =0.0001). An INR >2.6 was the
only independent predictor of bleeding. There were no
significant differences in major adverse cardiac events
between the two groups (5.8% vs. 4.9%, p =0.7).
In the study by Valencia et al. [24], 70 patients on
OAC treated with PCI-S were discharged either on TT
(64,2%), OAC plus clopidogrel (7,5%), OAC plus aspirin
(3%), or DAPT (25.4%). Adverse events were minor
bleeding in 11.4% of cases, major bleeding in 8.6%, myo-
cardial infarction 4.3%, stent thrombosis in 1.4%, and
death in 12.8%. Patients treated with TT were at
increased risk of bleeding complications.
In the prospective study by Gao et al. [25], 622 con-
secutive patients with atrial fibrillation underwent PCI-S
with DES. They were discharged on TT, DAPT, or the
combination of warfarin and a single antiplatelet agent.
At 12-month follow up, the combined incidence of death,
myocardial infarction, target vessel revascularization, stent
thrombosis, and stroke was in favour of TT. However, in
the TT group, respect to the combination of warfarin plus
a single antiplatelet agent and DAPT, a significantly
higher incidence of overall bleeding (11.8% vs. 7.4% vs.
5.1%, P=0.038), essentially driven by minor bleeding
events (8.8% vs. 5.0% vs. 3.3%, P=0.042), was observed.
A prospective multicenter registry, the MUSICA study,
included 405 patients from nine hospitals in Spain and
one in UK [26]. TT was administered to 68.6% of
patients, OAC plus an antiplatelet agent to 11.4%, and
DAPT to 20%. At 6 months, patients in TT groupexperienced a higher rate of bleeding (15% vs. 13% in
patients receiving OAC plus an antiplatelet agent, and
3.7% in patients receiving DAPT; p=0.03). Even though,
there were no differences in the incidence of major
bleedings among groups. The combination of OAC plus
an antiplatelet agent showed the worst rate of adverse
events in the whole cohort, especially in patients at
moderate–high thromboembolic risk.
In the STENTICO Registry [27] a total of 359 patients
treated with PCI with an indication for long-term OAC
from 40 French centers were included. In 234 patients
(65.2%) OAC therapy was discontinued and DAPT was
administered for about 30 days. One hundred and
twenty five patients were treated with TT (34.8%). The
stroke rate did not differ significantly between DAPT
(3.0%) and TT (0.8%) groups. Severe and moderate
bleeding, according to the GUSTO criteria, occurred in
2.1% of patients in DAPT and in 6.4% of patients in TT
(p =0.04). A significant difference in bleeding rate was
found between the femoral and radial approaches (10.3%
vs. 3.8%, p =0.01). The authors concluded that, adding
DAPT to pre-existing OAC therapy increases the post-
PCI bleeding risk. Temporary discontinuation decreased
this bleeding risk but tended to increase the risk of
stroke. A radial approach for PCI could be a good alter-
native to avoid bleeding.
In the post-hoc analysis of the BASKET trial [28] 44
patients on OAC were considered (5.4% of the whole
population). After stenting, all patients were assigned to
DAPT in addition to OAC for at least 6 months, and
were followed for 3 years. Overall, there were 25 early
(i.e. during the index hospitalization) bleeding events
(during warfarin therapy in 2 cases), and 26 late bleeding
events (during warfarin therapy in 8 cases). Most early
bleedings were directly related to the intervention. The
most important risk factor for total bleedings was anti-
thrombotic regimen. In patients treated with TT the total
bleeding rate was considerably higher (OR= 4.6), result-
ing mainly from late bleedings (OR= 9.3). The annual
rate of bleedings was 6.1% in patients taking warfarin,
only 0,8% in those not taking it.
In the retrospective analysis by Halbfass et al. [29], 117
patients with atrial fibrillation treated with PCI-S were
evaluated. Fifty-three patients (45.3%) received TT after
PCI. Two out of 13 patients (15%) with a major bleeding
were on DAPT, 9 out of 13 (69%) were on OAC, but
only one patient (8%) was on TT while the bleeding oc-
curred. Only two out of six patients with a thrombo-
embolic complication were on OAC at the time of the
occurrence. The probability of the occurrence of adverse
events in patients on TT vs. patients without TT after
PCI-S was similar (p= n.s.).
In a small France study [30], 50 consecutive patients
underwent PCI-S without interrupting oral anticoagulant
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events or excess bleeding were observed at 1 month.
Only one patient had a minor hemorrhage 8 days after
procedure.
In a retrospective study on PCI-s patients [31], Olson
et al. evaluated 175 patients treated with TT matched
with 339 patients treated with DAPT. There were 25
(14.3%) major hemorrhages in the TT group and 10
(3.0%) major hemorrhages in the DAPT group (OR 9.0;
95% CI, 3.1–26.1). Patients in the TT group had a
greater likelihood of MACE compared to patients in the
DAPT group (OR 2.0; 95% CI 1.1–3.8). Post-stent treat-
ment with TT was associated with a substantially greater
likelihood of major events than treatment DAPT.
In the study by Baber et al. [32], 454 consecutive
patients who underwent PCI-S with DES were discharged
on TT either conventional (n= 170) or with modified anti-
platelet regimen (daily aspirin and every other day clopi-
dogrel) (n= 284). There were no differences in 1-year rates
of death, myocardial infarction, stent thrombosis or target
lesion revascularization between patients receiving a con-
ventional compared to a modified antiplatelet regimen
(11.8 vs. 11.3, respectively). There were no differences also
in the rates of TIMI major bleeding between the two
groups (1.1% vs. 1.4%).
Data from RIKS-HIA and SCAAR registries concern-
ing 25091 patients treated with PCI-S in Sweden were
analyzed [33]. OAC was prescribed in 1183 patients,
56% of whom were on TT. TT was associated with four
times higher risk of any bleeding than OAC plus aspirin,
adj. RR 4.27 (95% CI 1.2-15.1), but a lower incidence of
death or MI than OAC plus clopidogrel adj. RR 0.63
(95% CI 0.40-0.99).
In a retrospective Japanese study [34], 575 consecutive
patients implanted with DES were analyzed. During a
median follow-up of 459 days, 14 (2.7%) patients receiv-
ing DAPT, and 9 (18%) receiving TT reported major
bleeding complications (p< 0.001). These results show
that adding warfarin to DAPT was associated with an
increased risk of subsequent major bleeding. On the
other hand, the incidence of MACE did not differ be-
tween the two groups (p= n.s.).
In a small study conducted in Barcelona [35], the
authors reviewed data from consecutive patients on
OAC who underwent PCI-S and were prescribed TT.
Overall, hemorrhages were higher in patients receiving
TT than on DAPT (90.6 and 8.29 bleedings/100 patient-
years, respectively (RR 10.9; p< 0.01). Nevertheless, two
patients suffered severe hemorrhages during DAPT (one
traumatic subdural hematoma and one hemathemesis,
both resolved uneventfully), accounting for a rate of 2.76
bleedings/100 patient-years, compared to none during
TT (p= 0.4). They concluded that patients treated with
PCI-S who also have indication for OAC can beprescribed a second antiplatelet drug (usually clopido-
grel) with no increase in severe hemorrhages, but a sig-
nificantly higher rate of non-severe hemorrhages (16-fold
increased risk) that is unrelated to differences in anti-
coagulation control.
In a very recent publication regarding 362 Korean AF
patients undergoing PCI-S [36] 20.2% of patients
received TT. Globally, warfarin was prescribed to 84
patients (23.2%). Cilostazol was used in addition to dual
antiplatelet therapy in 35% of the patients who did not
receive warfarin. The anticoagulation group was slightly
younger than the non-anticoagulation group. Overall,
45.5% of patients had a CHADS2 score of ≥2. The indi-
cations for PCI were chronic stable angina (43%) and
acute coronary syndrome (57%). DESs were used in
most cases. The use of warfarin did not affect the inci-
dence of major adverse events, including death, myocar-
dial infarction, target vessel revascularization, a bleeding
episode or stroke, but it was associated with an
increased risk of major bleeding (p= 0.002) by Kaplan-
Meier survival analysis (Log-Rank test). Independent
predictors for major bleeding were total stent number
(HR 2.020) and warfarin use (HR 7.564). Authors con-
cluded that oral anticoagulation therapy after PCI may
increase hemorrhagic events in Korean AF patients.
Consideration for clinical practice
As derived from the data above, TT appears the best
antithrombotic regimen to prevent both stent throm-
bosis and stroke in AF patients undergoing PCI-S. As
long as this regimen was carried out in fact, such com-
plications were only exceptionally reported. In the study
by Karjalainen et al. [14] however, one of the two (1.9%)
episodes of stent thrombosis occurred soon after clopi-
dogrel withdrawal. Indeed, among the patients examined
by Rubboli et al. [16] the only thrombotic event (i.e.,
subacute stent thrombosis) was observed with the com-
bination of warfarin and aspirin. As regards stroke pre-
vention, the study by Karjalainen et al. [14] is again in
support of TT (2.8%) and, as expected, against DAPT
(8.8%). In two studies comparing TT with DAPT for
more than 1 month, thromboembolic events and death
were increased in patients on DAPT, while subacute stent
thrombosis were not different [16,18] In the study by Gao
et al. [25] whenever DAPT was used, alone or in com-
bined with OAC, the incidence of stent thrombosis was
about two times less frequent. In addition, compared with
DAPT, the incidence of stroke was about four times lower
in regimens including warfarin, combined to either one or
two antiplatelet agents. In the study by Sambola et al. [26],
in the subgroup classified at moderate to high thrombo-
embolic risk, the overall clinical benefit of TT was evident:
the incidence of thromboembolic complications was five
to seven times lower than in the other groups.
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the exception of a few studies [17,23,26,29,30,33,35], the
overall risk of bleeding, especially major, with the combin-
ation of warfarin, aspirin, and clopidogrel was found to be
relevant and higher (up to 5-fold) than with DAPT. The
overall incidence of major adverse cardiovascular events
and bleeding events is reported in Table 2. The absolute
incidence of major hemorrhages however, appears low, at
least in the short term, i.e. 1 month (about 2.5%). Admin-
istration of numerous antithrombotic drugs, such as dur-
ing bridging therapy or use of glycoprotein IIb/IIIa
inhibitors, seem to increase the short-term hemorrhagic
risk after PCI-S [11,14,16]. Data from the GRACE registry
[17] reported similar in hospital rates of major bleeding inTable 2 Incidence of MACCE and bleeding events in patients
Author MACCE (%)
All cause mortality MI
Orford JL et al. [9] NR NR
Mattichak SJ et al. [10] 3 29
Khurram Z et al. [11] 0.9 0
Porter A et al. [12] NR NR
Lip GYH & Karpha M [13] NR NR
Karjalainen PP et al. [14] 8.7 10
DeEugenio D et al. [15] 1 NR
Rubboli A et al. [16] 0 0
Nguyen MC et al. [17] 5.1 3.3
Rogacka RCA et al. [18] 3.9 1.6
Ruiz-Nodar JM et al. [19]^ 17.8 6.5
M.-Fernandez S et al. [20] 5.9° NR
Sarafoff N et al. [21] 10.7 3.7
Maegdefessel L et al. [22] 7.1 0
Rossini R et al. [23] 2 NR
Valencia J et al. [24] NR NR
Gao F et al. [25] 4.4 2.9
Sambola A et al. [26] 6.8 NR
Gilard M et al. [27] 8 5
Hälg C et al. [28] NR NR
Halbfass P et al. [29] NR NR
Helft G et al. [30] 0 6
Olson KL et al. [31] 14.8° 0
Baber J et al. [32] 5.9 1.8
Persson J et al. [33] 3.6 9
Uchidab Y et al. [34] 8 0
Guasch E et al. [35] NR NR
Jang SW et al. [36] 3.6 3.6
MACCE= major adverse cardiovascular and cerebrovascular events ; OAC= oral antic
PCI-S= percutaneous coronary intervention with stent implantation; NR= not report
¥ transfusions * requiring hospitalization § in-hospital events ^ data are related to a
death.patients with TT (5,9%) compared to warfarin plus a single
antiplatelet agent (4,6%). Another study (26) reported
similar rates of major and minor bleeding after 2 years fol-
low up in patients with TT (27,5%) versus DAPT (18%).
Most of the bleeding occurred in the gastrointestinal tract.
In the study by Gao et al. [25], TT was characterized by a
significant higher incidence of overall bleeding, even if the
difference was essentially driven by minor bleeding. Not-
ably, 72% of all the INR measurements were within the
target range (1,8 - 2,5). In the by Sambola et al. study [26],
TT was associated with the highest incidence of bleeding
events (once again mainly minor bleeding).
The meta-analysis by Zhao et al. [37] which included
nine studies [10,11,14,15,19-23], demonstrated that TTwith an indication for OAC receiving TT after PCI-S
Bleeding (%)
Ichemic Stroke Overall Major Overall
NR 0 3.1 9.2
0 NR NR 21¥
0 NR 6.6 21.5
NR NR 1 11
NR NR 0 0*
3.2 25.1 8.2 NR
NR NR 13.5 NR
0 0 14.3 20
0.7 NR 5.9§ NR
NR 23.6 4.7 7.1
1.7 26.5 14.9 27.5
NR 25.5 27.4 NR
1.1 14.1 1.4 9.1
0 NR 0 NR
1 5.8 2.9 10.8
NR NR NR NR
0.7 8.8 2.9 11.8
0.3 7.9 4.3 15.5
0.8 NR 5.6 18.4
NR NR 6.1 NR
NR 21 8 NR
0 6 0 2
NR 15.4 14.3 NR
NR 11.8 1.1 4.6§
NR NR 2.3 4.1
4 22 18 38
NR NR 0 12.1
1.2 26.2 10.7 13.1
oagulation; TT= triple therapy;
ed.
nticoagulated patients, 88% of whom treated with TT ° cardiovascular-related
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mortality, at the price however of an increased bleeding
risk. Almost all bleeding events, however, occurred in the
first 6 months after discharge and were often associated
with supra-therapeutic INR levels [22,23]. On the other
hand, the prevalence of major bleeding increases with TT
treatment duration, from 2,6% to 4,6% at 30 days, to
13,9% at 6 months, and 7,4% to 10,3% at 1 year [38]. Pos-
sible explanation for the higher bleeding events are
advanced age, female gender, comorbidities like renal
dysfunction and previous major bleeding, glycoprotein
IIb/IIIa inhibitors use, and smoking [14]. Of note, also
anemia resulted a risk marker of both mortality and
hemorrhagic complications [12,15,16].
In summary, in patients with AF at moderate to high
risk of stroke undergoing PCI-S, TT is generally advis-
able [39,40]. Careful INR monitoring is important, as
well as individual bleeding risk evaluation [3,41]. Since
most bleeding events appear to be gastrointestinal
[10,15], gastric protection with proton-pump inhibitor
should be considered in all cases on TT (such as on
DAPT), being the association of a thienopyridine a risk
factor for upper gastrointestinal events in low-dose aspirin
users, whereas the use of proton-pump inhibitor is consid-
ered a protective factor [42]. Restrictive use of DES is
recommended to keep the duration of TT as short as
possible [6,38,43]. In order to reduce early hemorrhagic/
access site complications, radial approach and uninter-
rupted anticoagulation (INR value > 2) instead of heparin
bridging should be considered [3,44-48].
At present, minimal data are available on the combin-
ation of warfarin and clopidogrel, although in the small
subgroup of patients receiving warfarin plus clopidogrel
in the study by Karjalainen et al. [14], and in the study
by Ait mokhtar et al. [49] the efficacy appeared to be
good. Nevertheless, according to another study [26],
the OAC plus a single antiplatelet agent was classified
as having the worst profile of risk, especially in pa-
tients at moderate to high thromboembolic risk. In ad-
dition to that, the safety profile as observed in the study
by Karjalainen et al. [14] appears as suboptimal as that
of TT, making therefore the combination of OAC and
clopidogrel a relatively attractive alternative to TT.
When a very high hemorrhagic risk is perceived, such
as with a HAS-BLED (Hypertension with systolic >160
mmHg, Abnormal renal/liver function, Stroke history,
Bleeding, Labile INRs, “Elderly” with age ≥65 years,
Drugs/alcohol usage) [50] score ≥3, the balloon-only
angioplasty strategy may be considered. Although being
associated with a higher restenosis risk, avoidance of
stent implantation, and consequently of long thyenopiri-
dine use, might reduce the bleeding risk [51]. When a
stent is required, placement of bare-metal stent should
be generally preferred over a DES. The combination ofwarfarin and aspirin should not be used, owing to the
suboptimal efficacy on adverse cardiac events observed
both in the historical trials comparing such regimen with
DAPT [7], and in the studies by Karjalainen et al. [14]
and Rubboli et al. [16], where stent thrombosis and/or
myocardial infarction were solely or mainly observed
with that antithrombotic treatment. Treating long
lesions, small vessels, diabetic patients, in-stent resten-
osis generally advocate the use of DES. In this case, a
second-generation DES, such as everolimus or zotaroli-
mus eluting stents, should be preferred [52] owing to
the associated lower risk of thrombosis rate [53], which
may likely allow for a shorter (i.e., 3 months) duration of
clopidogrel (and hence TT).
Future perspectives
Dabigatran, an oral anticoagulant from the class of the
direct thrombin inhibitors, administered in two fixed
doses (110 or 150 mg twice daily) in patients with non-
valvular AF at moderate to high risk of stroke, demon-
strated to be more effective than warfarin in reducing
stroke/systemic embolism, and less likely to cause major
bleeding complications [54]. Apixaban, an oral direct
factor Xa inhibitor, administered at a dose of 5 mg twice
daily in patients with non-valvular AF at moderate to
high risk of stroke was superior to warfarin in prevent-
ing stroke/systemic embolism, reducing overall mortality
and causing less bleeding [55]. Rivaroxaban, another oral
factor Xa inhibitor, at the dose of 20 mg/die recently
demonstrated to be non inferior to warfarin for the pre-
vention of stroke/systemic embolism in AF patients at
relatively high risk of stroke. In all three studies, the in-
cidence of intracranial and fatal bleeding occurred less
frequently with the novel oral anticoagulants [56].
The use of the oral factors Xa inhibitors rivaroxaban
and apixaban in combination with DAPT, in patients
with acute coronary syndrome, has been evaluated in
the ATLAS ACS 2–TIMI 51 [57] and APPRAISE-2 [58]
studies. In the ATLAS ACS 2-TIMI 51 study, patients
were randomized to receive twice-daily doses of either
2.5 mg or 5 mg of rivaroxaban, on top of the therapy, or
placebo. Rivaroxaban reduced the risk of the composite
end point of death from cardiovascular causes, myocar-
dial infarction, or stroke. Rivaroxaban increased the risk
of major bleeding and intracranial hemorrhage respect
to DAPT, but not the risk of fatal bleeding. In the
APPRAISE-2 study patients with a recent acute coronary
syndrome, and at least two additional risk factors for re-
current ischemic events, were randomized to receive
apixaban, at a dose of 5 mg twice daily, or placebo, in
addition to mono or dual antiplatelet therapy. The trial
was terminated prematurely after recruitment of 7392
patients because of an increase in major bleeding events
with apixaban (1.3% vs. 0.5%, p= 0.001), in the absence
Table 3 Summary of the suggested antithrombotic strategies arising from published studies and guidelines, applied to
patients with AF undergoing PCI-S
Moderate-high TE risk
(CHADS2 score ≥ 2)
• use radial approach • use radial approach
• prefer uninterrupted OAC (INR > 2) • prefer uninterrupted OAC (INR > 2)
• prefer BMS (DES allowed) • consider balloon-only PCI or CABG
• at discharge prescribe TT for 1–6 months • prefer BMS (DES to be avoided)
• target INR to 2.0-2.5 • at discharge prescribe TT for 2–4 weeks
• prescribe gastric protection throughout DAPT/TT •target INR to 2.0-2.5
• prescribe gastric protection throughout DAPT/TT
Low TE risk
(CHADS2 score 0–1)
• use either radial/femoral approach • prefer radial approach
• withdraw OAC • withdraw OAC
• use either BMS/DES • prefer BMS (DES allowed, preferably last generation)
• at discharge prescribe DAPT for 1–6 months • at discharge prescribe DAPT for 2–4 weeks
• prescribe gastric protection throughout DAPT • prescribe gastric protection throughout DAPT
Low bleeding risk (HAS-BLED score 0–2) Moderate-high bleeding risk (HAS-BLED score ≥ 3)
AF =atrial fibrillation; PCI-S = percutaneous coronary intervention with stent implantation; OAC = oral anticoagulation; INR =international normalized ratio; BMS =
bare metal stent; DES = drug-eluting stent; TT = triple therapy; CABG = coronary artery bypass graft; DAPT = dual antiplatelet therapy
*for CHADS and HAS-BLED scores’ details see text.
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events (the primary outcome of cardiovascular death,
myocardial infarction, or ischemic stroke occurred in
7.5% of patients assigned to apixaban and in 7.9% of
patients assigned to placebo, p= 0.51). It would be inves-
tigated if these new anticoagulant agents can have a role
in patients with AF treated with PCI-S.
On the other side, novel P2Y12 receptor antagonists,
such as prasugrel and ticagrelor, showed to be superior
to clopidogrel in reducing major adverse cardiovascular
events [59,60], but the incidence of TIMI major bleeding
was significantly higher compared to clopidogrel. Thus,
at present TT with OAC, aspirin and prasugrel/ticagrelor
appears not advisable owing to the likely elevated risk of
bleeding.
At the same time, it seems that a key issue will be to
test whether DAPT can be shortened in patients treated
with the newest generations of DES, either second gen-
eration DES [61], or DES with bioresorbable polymers
and fully bioresorbable stents, as the short term degrad-
ation of the polymer or of the whole scaffold should
avoid per se late and very late stent thrombosis [62,63].
While waiting for further and higher quality data
regarding the optimal antithrombotic regimen for AF
patients requiring OAC for associated moderate to high
risk of stroke and who are submitted to PCI-S, TT of
warfarin, aspirin and clopidogrel with a duration as short
as possible should represent the standard of care at least
in patients at low to moderate risk of bleeding.
Conclusions
In accordance with the currently available evidence, man-
agement recommendations of patients with AF undergoingPCI-S have been recently issued by experts’ panels and
official Scientific bodies [1-5]. Overall, a consensus on TT
is apparent. As properly acknowledged in these papers
however, the current recommendations arise from limited
and of relative poor quality evidence. Accordingly, most of
these recommendations are graded IIa (that is, uncertain
benefit over risk) with a level of evidence mostly C (that
is, arising from experts’ consensus or small studies or
observational registries). We suggest a practical summary
of the mostly accepted recommendations, as presented in
Table 3.
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